Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Digoxin/furosemide - Cutanea Life Sciences

Drug Profile

Digoxin/furosemide - Cutanea Life Sciences

Alternative Names: CLS-003; Furosemide/digoxin; ICVT; Ionic contra viral therapy

Latest Information Update: 16 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henderson Morley
  • Developer Cutanea Life Sciences; Henderson Morley
  • Class Antihypertensives; Antivirals; Glycosides; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics; Potassium channel antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Genital warts; Vulvar intraepithelial neoplasia; Warts
  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Infectious keratoconjunctivitis

Most Recent Events

  • 30 Oct 2018 Cutanea Life Sciences terminates a phase II trial for Genital warts and Vulvar intraepithelial neoplasia in Netherlands (Topical) (NCT03334240)
  • 10 Aug 2018 Phase-II clinical trials in Actinic keratosis (In adults, In the elderly) in Netherlands (Topical) (EudraCT2018-000034-36) (NCT03684772)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top